Iohexol caused less marked overall hemodynamic alterations and a lower incidence of significant changes in pressure and heart rate compared to sodium methylglucamine diatrizoate.
Does iohexol improve safety and hemodynamic stability compared to sodium methylglucamine diatrizoate in patients undergoing cardiac catheterization?
Iohexol provides comparable diagnostic quality to standard ionic contrast but with fewer hemodynamic perturbations, making it potentially preferable for high-risk patients undergoing cardiac angiography.
Ionic contrast agents currently used in cardiac angiography are well tolerated but have certain negative effects. In a five-center study of 273 patients undergoing cardiac catheterization, safety and efficacy of the new nonionic contrast agent, iohexol, were compared with that of the standard ionic material, sodium methylglucamine diatrizoate. Contrast injections were made into the left ventricle and left and right coronary arteries in all patients. Left ventricular, systemic arterial and pulmonary capillary wedge pressures, and electrocardiogram lead II were recorded for 2 minutes. Following the first right and first left coronary injection, systemic arterial pressure and electrocardiographic recordings were made for 1 minute. After each subsequent coronary injection, recordings were made for 20 seconds. Both agents were found to be safe and both provided good diagnostic information. Iohexol was seen to cause both less marked overall hemodynamic alterations and a lower incidence of significant changes in pressure and heart rate. Iohexol may have an important role in coronary angiography and left ventriculography, particularly in high-risk patients, because of its lesser effect on heart rate and blood pressure.
Bettmann et al. (Tue,) conducted a other in Cardiac catheterization (n=273). Iohexol vs. Sodium methylglucamine diatrizoate was evaluated on Safety and efficacy (hemodynamic alterations, changes in pressure and heart rate). Iohexol caused less marked overall hemodynamic alterations and a lower incidence of significant changes in pressure and heart rate compared to sodium methylglucamine diatrizoate.